A 61-year-old woman, with a lifelong history of a giant congenital melanocytic nevus involving the occipital scalp, posterior neck and shoulders, and upper back, presented with a six-month history of an ulcerated tumour in the occipital region ([Fig. 1a](#F1){ref-type="fig"}, [1b](#F1){ref-type="fig"}, [1c](#F1){ref-type="fig"}). Magnetic resonance imaging confirmed the presence of an exophytic cutaneous tumour measuring 11.5 cm in greatest diameter as well as spinal stenosis in the area of C6 and C7. Abnormal laboratory studies included an increased C-reactive protein and an elevated serum S100 level (0.122 mcg/l). Radiographic and ultrasonographic studies failed to show evidence of disease progression to lungs, lymph nodes or abdominal structures. A wide local excision was done, and the histopathology confirmed the diagnosis of malignant melanoma with a maximum thickness of 16 mm ([Fig. 1d](#F1){ref-type="fig"}, [1e](#F1){ref-type="fig"}, [1f](#F1){ref-type="fig"}). Additional reexcision with 1,5cm safety margins was planned. Immunohistopathological stainings with HMB-45 (diffusely positive) and S-100 showed a strong positive reaction. The patient denied sentinel lymph node biopsy. Tumour was staged as IIB (T4aN0M0). A prophylactic interferon therapy (3 MU/m^2^, 3 x weekly) was planned.
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Congenital melanocytic nevus (CMN) is defined, clinically, as a melanocytic lesion present at birth or which develops during infancy from preexistent melanocytes \[[@ref1], [@ref2]\]. The risk of developing melanoma over a CMN is a nowadays very well established subject \[[@ref1], [@ref3]\]. It is believed that this risk is directly proportional to nevus size, varying from 2.6% to 4.9% for small and medium nevi and from 6% to 20% for giant nevi \[[@ref3]\]. For these reasons, surgical resection of giant congenital nevi is frequently recommended before puberty and when located in areas difficult to monitor \[[@ref2]\]. Nowadays, there is tremendous uncertainty regarding how giant congenital melanocytic nevi (GCMN) should be treated. The standard approach to patients with GCMN is based on two main considerations: (1) obtain an acceptable cosmetic result to decrease the psychosocial inconvenience to the patient, and (2) attempt to minimise the risk of malignancy.

To date, no absolute guidelines to treat these nevi have been given to our knowledge, and therefore, this subject remains one of the most controversial issues in dermatologic surgery and dermatologic oncology \[[@ref4]-[@ref6]\].

Complete removal of the GCMN is usually difficult and very often impossible without functional or cosmetic mutilation. Moreover, even after complete excision of GCMN down to the muscle fascia, the malignancy risk is not completely eradicated as malignant melanoma can occur at extracutaneous sites \[[@ref7]\].

The most promising results of treating GCMN were originally reported by Moss in 1987 \[[@ref8]\]. He performed curettage on GCMN during the first weeks of life to remove the superficially distributed nevus cells based on the fact that at that time, there seems to be a cleavage plane between the upper and the lower dermis. This technique offers the best alternative to classic surgery when the nevi are too large to perform complete excision, and it is a technique that is of benefit for these patient groups \[[@ref9]\]. Treatment with targeted therapies, after phenotype characterization, should also be considered in selected cases \[[@ref10], [@ref11]\].
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